Managing ADOA: Current Care and Future Hope

While there is currently no approved cure for Autosomal Dominant Optic Atrophy (ADOA), the landscape of care is changing rapidly. Managing the condition today involves a combination of supportive care to maximize quality of life and the exploration of “off-label” and emerging therapies that aim to slow or stop the progression of the disease.

The Current Standard of Care

Because ADOA typically progresses slowly, the primary goal of the current standard of care is symptom management and preservation of function ^[1][2].

• Low Vision Rehabilitation: This is a cornerstone of care. It is important to know that low-vision rehab is not just getting a stronger glasses prescription. It involves working with an occupational therapist or specialist to acquire specialized lighting, high-contrast digital readers, text-to-speech software, and mobility strategies to help patients remain independent and successful in school or work ^[3].
• Regular Monitoring: Consistent check-ups using OCT (to measure nerve thickness) and visual field testing are essential to document stability or catch any new changes early ^[4][5].

For more detailed information on long-term care and diet, visit Thriving with ADOA: Monitoring and Lifestyle.

Off-Label and Supportive Treatments

Some patients and doctors explore medications that are not yet officially approved for ADOA but may offer benefits based on similar conditions.

• Idebenone: This is the only approved medication for a similar condition called LHON (Leber Hereditary Optic Neuropathy) ^[6][7]. In LHON, it helps “bypass” the broken part of the mitochondria to restore energy production ^[8][9]. While not universally proven for ADOA, some studies suggest it may help stabilize or even improve vision in some patients with OPA1 mutations ^[2][10].
• Metabolic Support: Research is investigating whether “boosting” the health of the mitochondria can help. This includes strategies like using NAD+ boosters or specific antioxidants to reduce oxidative stress in the eye ^[11][2].

Emerging Investigational Therapies

We are currently in a “golden age” of research for ADOA, with several high-tech therapies in development. Note: These therapies are currently in early-phase clinical trials, meaning it will be several years before they are widely available, but they represent a shift toward treating the root genetic cause.

1. Antisense Oligonucleotides (ASOs) - STK-002: This is one of the most promising areas of research. STK-002 is a “genetic patch” that tells the cell to ignore a mistake in the OPA1 gene, allowing the body to produce more healthy OPA1 protein ^[12]. Preclinical trials have shown it can improve mitochondrial health and increase protein levels ^[12].
2. Gene Therapy: Scientists are working on using harmless viruses (AAV vectors) to deliver a healthy copy of the OPA1 gene directly into the retinal cells ^[13][2]. This “gene augmentation” has shown success in animal models and is moving toward human trials ^[13].
3. TANGO Technology: This approach aims to naturally boost the output of the healthy gene that patients already have, compensating for the mutated one ^[2].